Giovanni Barosi

TL;DR: It is reported that TGF‐β1/miR‐382‐5p/SOD2 axis deregulation in PMF cells is linked to ROS overproduction that may contribute to enhanced oxidative stress and inflammation.

TL;DR: Recommendations on the use of BV are issued during a consensus project, sponsored by the Italian Society of Hematology and its affiliate societies, and Società Italiana di Ematologia Sperimentale and Gruppo Italiano Trapianto di Midollo Osseo.

TL;DR: Ruxolitinib reductions in splenomegaly and spleen length reductions were rapid and occurred within the first few weeks of therapy, and no DLT has occurred with the first 3 dose levels in pts with PLTs 75–99 × 109/L.

TL;DR: The accumulation of mutated alleles in the JAK2V617F clone or the selective acquisition of a proliferative advantage in the wt clone are two relevant routes to BT in PMF.

TL;DR: The long-term efficacy and safety of ruxolitinib in patients with ET from an open-label, phase II study (INCB18424-256; [NCT00726232];1) was reported, with platelet count decreased rapidly after initiation of therapy and remained relatively stable over time.